Zobrazeno 1 - 10
of 15
pro vyhledávání: '"S Ruiz-Fuentes"'
Autor:
R Morón-Romero, S Ruiz-Fuentes, C García-Fernandez, S. Belda-Rustarazo, C Gómez-Peña, P Gómez-Nieto
Publikováno v:
Eur J Hosp Pharm
Background The prescriptions of biologics are increasing as new indications and drugs are authorised. Since biosimilar drugs were introduced in the pharmaceutical market, they have become an alternative to continuing with the demand at competitive co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09bb1fd73e7a5ef79e21479009ea8609
https://europepmc.org/articles/PMC7535604/
https://europepmc.org/articles/PMC7535604/
Publikováno v:
Eur J Hosp Pharm
Background Based on available evidence and its benefit/risk balance, acetylsalicylic acid (ASA) is the first-line antiplatelet drug of choice for secondary prevention of cardiovascular events. It is recommended to be used at low doses, not exceeding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cd882a2bd581259b62323aed70a3cfe
https://europepmc.org/articles/PMC7535577/
https://europepmc.org/articles/PMC7535577/
Autor:
R Morón Romero, M Valle Corpas, I Casas Hidalgo, C García Fernández, Mdc Gonzalez Medina, S Belda Rustarazo, C Gómez Peña, S Ruiz Fuentes
Publikováno v:
European Journal of Hospital Pharmacy. 23:A88.2-A89
Background Administration of immunosuppressive drugs can cause reactivation of hepatitis B virus (HBV), both asymptomatic and fulminant hepatitis. In July 2014, the Spanish Agency for Medicines and Health Products (AEMPS) published a press release in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2aa52fc707587166bc0feba36680c756
https://doi.org/10.1136/ejhpharm-2016-000875.200
https://doi.org/10.1136/ejhpharm-2016-000875.200
Autor:
A Caballero Romero, C Gómez Peña, R Morón Romero, C García Fernández, Mdc Gonzalez Medina, M Valle Corpas, S Ruiz Fuentes, D Blanquez Martinez, I Casas Hidalgo
Publikováno v:
European Journal of Hospital Pharmacy. 22:A15.1-A15
Background Hormone treatment based on analogues of gonadotropin releasing hormone (GnRH) with antiandrogens is the first-line treatment for prostate cancer. This treatment produces a PSA reduction, improvement of symptoms and tumour regression. When
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6cc576655a8b3c1f38150926ecb68fc
https://doi.org/10.1136/ejhpharm-2015-000639.35
https://doi.org/10.1136/ejhpharm-2015-000639.35
Autor:
A Caballero Romero, R Morón Romero, C Medarde Caballero, C Gómez Peña, C García Fernández, C Fernandez Lopez, S Ruiz Fuentes, S Belda Rustarazu, MC González Medina, D Blanquez Martinez
Publikováno v:
European Journal of Hospital Pharmacy. 21:A8.2-A8
Background Asthma treatment with omalizumab is very expensive. The transfer of omalizumab dispensing from community to hospital pharmacy in April 2012 increased spending. This turned the spotlight on prescription practice. Purpose To assess the diffe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f253c96c940ef0ca1830a41ca6fc931
https://doi.org/10.1136/ejhpharm-2013-000436.20
https://doi.org/10.1136/ejhpharm-2013-000436.20
Autor:
CM Valencia Soto, S Ruiz Fuentes, C Medarde Caballero, C Fernandez Lopez, S Belda Rustarazo, R López Sepúlveda, C García Fernández, D Blanquez Martinez, C Gómez Peña, A Caballero Romero
Publikováno v:
European Journal of Hospital Pharmacy. 21:A126.2-A126
Background The use of intracameral cefuroxime is becoming more widely accepted for endophthalmitis prophylaxis (EP) after cataract surgery. Recently, the European Medicines Agency approved a single, sterile, unit dose of intracameral cefuroxime in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1686f8906892e3419c2ced3142d5950c
https://doi.org/10.1136/ejhpharm-2013-000436.310
https://doi.org/10.1136/ejhpharm-2013-000436.310
Autor:
CL Dávila Fajardo, R Morón Romero, A Caballero Romero, J Cabeza Barrera, C Gómez Peña, C García Fernández, C Medarde Caballero, S Belda Rustarazo, S Ruiz Fuentes, C Fernandez Lopez
Publikováno v:
European Journal of Hospital Pharmacy. 21:A137.2-A137
Background The coumarins have a narrow therapeutic window and there is wide inter- and intra-individual variability in dose requirements. Therefore, patients are monitored by measuring the international normalised ratio (INR). Recent discoveries show
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2353814f8df3d77d85580fde9dc704ef
https://doi.org/10.1136/ejhpharm-2013-000436.338
https://doi.org/10.1136/ejhpharm-2013-000436.338
Autor:
S. Belda-Rustarazo, C Medarde-Caballero, A Caballero-Romero, V Molina-García, D Blanquez-Martínez, C García-Fernandez, Lorena González-García, C. Fernández-López, S Ruiz-Fuentes, C Gómez-Peña
Publikováno v:
European Journal of Hospital Pharmacy. 21:A156.3-A157
Background Hospitals are putting in place more systems to improve the use of medicines. Since 2010, the Pharmacy Service has regularly been using a Medicines Reconciliation (MR) System at admission to the General Surgery, Urology and Orthopaedic Surg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::357d7213c27a8f4d6a48576e07a5f426
https://doi.org/10.1136/ejhpharm-2013-000436.384
https://doi.org/10.1136/ejhpharm-2013-000436.384
Autor:
CL Dávila Fajardo, JJ Fernández Ávila, Cantudo Cuenca, RM Damas Fuentes, D Blanquez Martinez, J Cabeza Barrera, C Gómez Peña, S Belda Rustarazo, C García Fernández, S Ruiz Fuentes
Publikováno v:
European Journal of Hospital Pharmacy. 21:A138.2-A138
Background HER2 (ERB2, neu) is a proto-oncogene that encodes a transmembrane protein with tyrosine kinase activity. Trastuzumab (Herceptin), a humanised monoclonal antibody that binds to the HER2 extracellular domain, is used to treat HER2-positive b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4692de293e0f70b485d971e9404c7881
https://doi.org/10.1136/ejhpharm-2013-000436.340
https://doi.org/10.1136/ejhpharm-2013-000436.340
Autor:
S Ruiz-Fuentes, S Belda-Rustarazo, A Caballero-Romero, C García-Fernandez, C Gómez-Peña, C Medarde-Caballero, D Blanquez-Martínez, C Fernández-López
Publikováno v:
European Journal of Hospital Pharmacy. 20:A70.2-A70
Background As the cytostatic medicines are a group of drugs with a narrow therapeutic index, it is necessary to develop new mechanisms to improve safety from prescription to administration in the hospital in order to avoid fatal errors. Purpose To de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85a3e8fafe94c32142b6e79c14839c44
https://doi.org/10.1136/ejhpharm-2013-000276.196
https://doi.org/10.1136/ejhpharm-2013-000276.196